BioNexus Gene Lab Corp. Selling and Marketing Expense
BioNexus Gene Lab Corp. (BGLC) reported Selling and Marketing Expense of $36.02 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-14
- BioNexus Gene Lab Corp. selling and marketing expense for the quarter ending 2026-06-30 was $36.02K, a 94.08% decline year-over-year.
- BioNexus Gene Lab Corp. selling and marketing expense for the quarter ending 2026-03-31 was $52.73K, a 90.25% decline year-over-year.
- BioNexus Gene Lab Corp. selling and marketing expense for the quarter ending 2025-12-31 was $35.64K, a 92.80% decline year-over-year.
- BioNexus Gene Lab Corp. selling and marketing expense for the quarter ending 2025-09-30 was $551.57K, a 55.71% decline year-over-year.
- BioNexus Gene Lab Corp. selling and marketing expense for fiscal 2025 was $1.74M, a 14.50% decline from fiscal 2024.
- BioNexus Gene Lab Corp. selling and marketing expense for fiscal 2024 was $2.03M, a 240.23% increase from fiscal 2023.
- BioNexus Gene Lab Corp. selling and marketing expense for fiscal 2023 was $596.86K.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.02K 10-Q · filed 2026-08-14 | $88.75K 10-Q · filed 2026-08-14 | $124.39K derived: sum of 3 quarters · filed 2026-08-14 | $675.96K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $52.73K 10-Q · filed 2026-05-15 | $88.37K derived: sum of 2 quarters · filed 2026-05-15 | $639.94K derived: sum of 3 quarters · filed 2026-05-15 | $1.25M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $35.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $587.21K derived: sum of 2 quarters · filed 2026-04-14 | $1.20M derived: sum of 3 quarters · filed 2026-08-14 | $1.74M 10-K · filed 2026-04-14 |
| 2025-09-30 | $551.57K 10-Q · filed 2025-11-14 | $1.16M derived: sum of 2 quarters · filed 2026-08-14 | $1.70M 10-Q · filed 2025-11-14 | $2.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $608.43K 10-Q · filed 2026-08-14 | $1.15M 10-Q · filed 2026-08-14 | $1.64M derived: sum of 3 quarters · filed 2026-08-14 | $2.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $540.70K 10-Q · filed 2026-05-15 | $1.04M derived: sum of 2 quarters · filed 2026-05-15 | $2.28M derived: sum of 3 quarters · filed 2026-05-15 | $2.42M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $494.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $1.74M derived: sum of 2 quarters · filed 2026-04-14 | $1.88M derived: sum of 3 quarters · filed 2026-04-14 | $2.03M 10-K · filed 2026-04-14 |
| 2024-09-30 | $1.25M 10-Q · filed 2025-11-14 | $1.38M derived: sum of 2 quarters · filed 2025-11-14 | $1.54M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $136.49K 10-Q · filed 2025-08-18 | $290.37K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $153.87K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $596.86K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |